Actinogen Medical - First patient dosed in Phase IIb XanaMIA study
Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first...
176 Views
Actinogen Medical - Pressing forward with Xanamem
Having shown cognitive activity in prior trials, Actinogen began its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive...
228 Views
Actinogen Medical - Phase IIb XanaMIA study opens first study site
Actinogen Medical has opened the first investigational study site for its Phase IIb XanaMIA trial of lead candidate Xanamem in patients with...
602 Views
Actinogen Medical - Taking steps to mitigate funding headwinds
Actinogen is refining the design of its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive impairment (CI) associated...
239 Views
Actinogen Medical - Funding the next stage of Xanamem development
Actinogen recently provided a Q423 quarterly update summarising that its two development programmes for lead candidate Xanamem remain on track,...
237 Views